Research in nanoparticle technology for drug delivery and bioimaging applications at DTU Nanotech has in the past year resulted in proprietary technology for enhancing the precision of cancer radiotherapy and a new spinout company.
Nanovi is a Copenhagen-based company that was founded in December 2010 and has later received funding from Novo Seed. Nanovi aims to raise the standard of radiotherapy without compulsory changes in current routines and equipment. Radiotherapy is an important element in modern cancer treatment, and more than 50% of cancer patients receive radiotherapy at least once after they are diagnosed with cancer.
Nanovi’s first product in development is focused on radiation treatment of lung cancer and the plan is to initiate clinical trials in 2012.
Contact: Associate Professor Thomas L. Andresen